08:36 AM EDT, 05/24/2024 (MT Newswires) -- BeiGene ( BGNE ) said Friday that several new analyses for its drug Brukinsa (zanubrutinib) show its efficacy and safety compared with other Bruton's tyrosine kinase inhibitors for treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma.

The drug showed "statistically significant improvements" in progression-free survival rates among high-risk patients and "a trend toward improvement" in overall survival, overall response, and complete response when compared with acalabrutinib and other rival treatments, the company said.